Database : HANSEN Search on : ERITEMA NODOSO [Subject descriptor] References found : 182 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 10

go to page

1 / 182

HANSEN

select to print Texto Completo-en

Id: 19695 Author: Jayalakshmi, P; Ganesapillai, T; Ganesan, J. Title: Correspondence: Erythema Nodosum Leprosum in Malaysians. Source: Int. J. Lepr;63(1):109-111, 1995. ^bilus. Descriptors: Eritema Nodoso/imunol Eritema Nodoso/fisiopatol Malásia/etnol Malásia/epidemiol Limits: Humanos Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1995/pdf/v63n1/v63n1cor08.pdf / en Location: BR191.1

2 / 182

HANSEN

select to print Texto Completo-en

Id: 19660 Author: Manandhar, Rakesh; LeMaster, Joseph W; Roche, Paul W. Title: Risk Factor for erythema nodosum leprosum. Source: Int. J. Lepr;67(3):270-278, Sept., 1999. tab, graf. Abstract: A retrospective study of new borderline lepromatous and lepromatous patients reporting for multidrug therapy (MDT) for leprosy at the Anandaban Leprosy Hospital, Kathmandu, Nepal, over an 8-year period was conducted to determine the prevalence of erythema nodosum leprosum (ENL), the time and frequency of reactions, and clinical and laboratory parameters associated with ENL. An overall prevalence of ENL in this cohort of 19% was found. One third of these reactions occurred in patients before MDT was given, one third in the first 6 months and one third after 6 months of treatment. Nearly 1 in 10 of the ENL reactions occurred in patients who had completed 2 years of MDT; 45% of patients with ENL had more than one episode. Data collected at the patients' first presentation was used to identify four major risk factors. Patients with lepromatous disease, skin infiltration or a bacterial index (BI) of > 4+ were at significantly increased risk. Patients older than 40 were at significantly decreased risk of ENL. There was a linear relationship in the risk of ENL with an increasing BI and an inverse relationship to increasing age. These observations should enable clinicians to recognize patients at first presentation who will be likely to develop ENL. (AU)^ien. Descriptors: Eritema Nodoso/compl Eritema Nodoso/fisiopatol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n3/v67n3a06.pdf / en Location: BR191.1

3 / 182

HANSEN

select to print Texto Completo-en

Id: 19361 Author: Rea, Thomas H. Title: Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous and lepromatous leprosy. Source: Int. J. Lepr;69(4):318-327, Dec., 2001. graf. Abstract: Changes in hemoglobin (HGB) and serum albumin (SA) concentration associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing the values obtained on the day thalidomide or prednisone therapy commenced, with each patients' preceding values. In three groups of ENL patients mean HGB values fell with statistical significance: 1) in 38 patients who had been begun on thalidomide in the decade of the 1990s and who had been receiving dapsone for a minimum of 6 months, mean HGB values fell from 13.19 gm/dl to 12.27 gm/dl, or 7.0%, p = 6.0 x 10(-6); 2) in 8 patients who were in the active patient file not overlapping with the preceding group, and who had been on dapsone for a minimum of 6 months, mean HGB values feel from 13.40 gm/dl to 11.96 gm/dl, or 10.7%, p = 0.0015; and 3) in 8 patients not overlapping with the preceding groups, who were treated with rifampin and minocylcine or clarithromycin mean HGB values fell from 13.25 gm/dl to 12.48 gm/dl, or 5.8%, p = 0.0035. In two groups of ENL patients SA values also fell with statistical significance: 1) in 34 patients who were begun on thalidomide in the decade of the 1990s and who had been on dapsone for a minimum of 6 months, mean SA values fell from 4.14 gm/dl to 3.77 gm/dl, or 8.9%, p = 1.2 x 10(-5); and 2) in 10 patients from the active file not overlapping with the preceding group, and who had been on dapsone for a minimum of 6 months, mean SA values fell from 4.45 gm/dl to 4.06 gm/dl, or 8.8%, p = 0.039. A brisk fall in HGB values was often accompanied by a fall in SA concentration, and vice versa. Recovery from extreme falls in HGB and SA values was complete in 13 weeks. Recovery occurred in the presence of continued dapsone treatment. The falls could be rapid, occurring too soon to be the result of decreased erythropoiesis or hepatic SA synthesis. This study provides no direct evidence as to the mechanism responsible for the fall in these two parameters, but an interleukin-6 mediated hemodilution is an attractive hypothesis. The ENL-associated fall in HGB values was distinct from dapsone-induced hemolysis and the anemia of chronic disease. The ENL-associated anemia is not a good reason to discontinue dapsone therapy.(AU)^ien. Descriptors: Hemoglobinas/imunol Albuminas/imunol Eritema Nodoso/imunol Hanseníase/imunol Limits: Humanos Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2001/pdf/v69n4/v69n4a03.pdf / en Location: BR191.1

4 / 182

HANSEN

select to print Texto Completo-pt

Id: 19270 Author: Rea, Thomas H. Title: Elevated platelet counts and thrombocytosis in erythema nodosum leprosum. Source: Int. J. Lepr;70(3):167-173, Sept., 2002. graf. Abstract: Changes in peripheral blood platelet counts associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing, in each patient, the value obtained on the day thalidomide therapy commenced with the average of the three preceding values. In the 11 patients studied, the mean platelet count rose from 235 to 322 x 10(3)/mm3, p < 0.001. In 3, the platelet count was above the normal limit, qualifying as thrombocytosis, in 7 the rise was appreciable, and in 2 it was negligible. In the 3 patients studied 1-2 weeks after beginning thalidomide, the mean count was 414 x 10(3)/mm3. Counts obtained after 3 or more weeks of thalidomide therapy were within normal limits. This study provided no direct evidence as to the mechanism responsible for the elevated platelet count, but mediation by interleukin-6 (IL-6) was concluded to be an attractive hypothesis, consistent with prior studies of IL-6 in reactive thrombocytosis and of IL-6 in ENL.(AU)^ien. Descriptors: Trombocitose/diag Trombocitose/fisiopatol Eritema Nodoso/diag Eritema Nodoso/fisiopatol Hanseníase/fisiopatol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2002/pdf/v70n3/v70n3a01.pdf / pt Location: BR191.1

5 / 182

HANSEN

select to print Texto Completo-pt

Id: 19206 Author: Pecoraro, Vicente Ernesto. Title: Eritema nodoso na lepra / Erythema nodosum in leprosy Source: Rev. bras. Leprol;10(1):67-83, mar. 1942. . Abstract: O autor tece comentários em torno da síndrome "Eritema nodoso" nas diversas moléstias, estudando em seguida as causas que podem desecadeá-lo na lepra. Estabelece ainda peculiaridades quanto à sua localização. Considera o "E.N." como a manifestação cutânea mais frequente do síndrome. "Reação leprótica". Observa que os casos avançado são os que mais frequentemente apresentam entre seus antecedentes, manifestações desse tipo, vendo possibilidades dessa erupção ser um índice de melhoria no prognóstico da doença. Sugere, sejam realizados estudos mais acurados nesse sentido. (AU)^ien. Descriptors: Hanseniase Hanseniase/clas Eritema nodosos/clas Eritema nodoso/diag Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/brasleprol/1942/pdf/v10n1/v10n1a02.pdf / pt Location: BR191.1

6 / 182

HANSEN

select to print Texto Completo-pt

Id: 19133 Author: Lippelt, Ary. Title: BCG e eritema nodoso em doente de lepra / BCG and erythema nodosum in leprosy patient Source: Rev. bras. Leprol;21(3):221-224, set. 1953. . Descriptors: Vacina BCG/imunol Vacina BCG/uso terap Eritema Nodoso/quimioter Eritema Nodoso/fisiopatol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/1953/PDF/v21n3/v21n3a05.pdf / pt Location: BR191.1

7 / 182

HANSEN

select to print Texto Completo-pt

Id: 18972 Author: Lima, Lauro de Souza. Title: Conceito atual de reação leprótica / The current concept of leprous reaction Source: Rev. bras. Leprol;17(3):151-154, set. 1949. ^btab. Descriptors: Hanseníase Dimorfa/imunol Hanseníase Virchowiana/imunol Hanseníase Tuberculóide/imunol Eritema Nodoso/imunol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/1949/PDF/v17n3/v17n3a03.pdf / pt Location: BR191.1

8 / 182

HANSEN

select to print Texto Completo-pt

Id: 18748 Author: Marques, M. B; Opromolla, Diltor Vladimir Ara£jo. Title: A talidomida no tratamento da reação leprótica. Source: Rev. bras. Leprol;37(1/4):41-49, 1970. ^btab. Descriptors: Hanseníase/quimioter Hanseníase/imunol Hanseníase/fisiopatol Hanseníase/reabil Talidomida/imunol Talidomida/farmacol Talidomida/uso terap Eritema Nodoso/compl Eritema Nodoso/fisiopatol Limits: Humanos Masculino Feminino Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/brasleprol/1970/PDF/v37n1-4/v37n1-4a03.pdf / pt Location: BR191.1

9 / 182

HANSEN

select to print Texto Completo-pt

Id: 18652 Author: Mello, Paulo Homem de. Title: Erythema nodosum leprosum e granuloma radiado de Miescher. Source: Rev. bras. Leprol;30(1/2):69-72, jan.-jun. 1962. . Abstract: To detect the presence of Mieschre's granuloma in erythema nodosum leprosum, fifty eight specimens biopsied from recent lesions were carefully examined, but in none of them is was found. The author points ou that, after the early positive reports of Portugal and Orbaneja, workers have repeatedly failed to observe the so-called radiated granulomas in erythema nodosum type of leprotic reaction. On the other hand, a review of the literature indicates that there is not yet, even in classical erythema nodosum, a general agreement regarding frequency, histogenesis and meaning of these estructures. The author concludes, therefore, that the ocasional histological findings, quoted above must not be over emphasized as an evidence of the identity between these two conditions. (AU)^ien. Descriptors: Eritema Nodoso/compl Eritema Nodoso/diag Eritema Nodoso/fisiopatol Granuloma/compl Granuloma/diag Granuloma/fisiopatol Hanseníase/compl Hanseníase/diag Hanseníase/fisiopatol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/brasleprol/1962/PDF/v30n1-2/v30n1-2a06.pdf / pt Location: BR191.1

10 / 182

HANSEN

select to print

Id: 18428 Author: Girdhar, Anita; Chakma, J. K; Girdhar, B. K Title: Pulsed corticosteroid therapy in patients with chronic recurrent ENL: a pilot study ..- Source: s.l; s.n; 2002. 4 p. . Abstract: A pilot study has been undertaken to compare the efficacy of small dose pulsed betamethasone therapy with need based oral steroids in chronic recurrent erythema nodosum leprosum (ENL) patients. Though this mode of therapy was well tolerated, no advantage with intermettnt steroid administration was observed. This coul have been on account of small dose of steroid given monthly. Treatment of chronic recurrent erythema nodosum leprosum (ENL) patients continues to be unsatisfactory, particularly, because of non-availability of thalidomide. Though corticosteroids are effective in suppressing all the manifestations and even restoring partially or fully the functional impairment, their side effects and dependence are equally troublesome. Based on (a) the reported efficacy and safety of intermittent use of corticosteroids in several immune complex mediated disorders (Cathcart et al 1976, Kimberly et al 1979), Lieblin et al 1981 and Pasricah & Gupta 1984) and (b) ENL (type II) reactions having similar pathology, a pilot study has been undertaken to see the efficacy and the tolerance of pulsed steroids in chronic ENL patients (AU). Descriptors: HANSENIASE VIRCHOWIANA/compl ERITEMA NODOSO/clas ERITEMA NODOSO/diag ERITEMA NODOSO/quimioter ERITEMA NODOSO/etiol ERITEMA NODOSO/imunol PULSOTERAPIA/tend PULSOTERAPIA/util ESTEROIDES/admin - BETAMETASONA/admin  BETAMETASONA/ef adv  NERVOS PERIFERICOS/les  FEBRE/etiol  INFECCOES OCULARES/etiol  RIM/les Limits: HUMANO Location: BR191.1; 00425/s

11 / 182

HANSEN

select to print

Id: 18426 Author: Teo, Steve K; Colburn, Wayne A; Tracewell, William G; Kook, Karin A; Stirling, David I; Jaworsky, Markian S; Scheffer, Michael A; Thomas, Steve D; Laskin, Oscar L Title: Clinical pharmacokinetics of thalidomide ..- Source: s.l; s.n; 2004. 17 p. ilus, tab, graf. Abstract: Thalidomide is a racemic glutamic acid derivative approved in the US for erythema nodosum leprosum, a complication of leprosy. In addition, its use in various inflammatory and oncologic conditions in being investigated. Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, respectively. More than 90% of the absorbed drug is excreted in the urine and faeces within 48 hours. Thalidomide is minimally metabolised by the liver, but is spontaneously hydrolysed into numerous renally excreted products. After a single oral dose of thalidomide 200mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (Cmax) of 1-2mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUCoo) of 18mg - h/L, apparent elimination half-life of 6 hours and apparent systemic clearence of 10 L/H. Thalidomide pharmacokinetics are best described by a one-comportment model with first-order absorption and elimination. Because of the low solubility of the drug in the gastrointestinal tract, thalidomide exhibits absorption rate-limited pharmacolinetics (the 'flip-flop' phenomenon), with its elimination rate being faster than in absorption rate. The apparent elimination half-life of 6 hours therefore represents absorption, not elimination. The 'true' apparent volume of distribution was estimated to be 16L by use of the faster elimination-rate half-life. Multiple doses of thalidomide 200 mg/day over 21 days cause no change in the pharmacokinetics, with a steady-state Cmax (Cssmax) of 1.2 mg/L. Simulation of 400 and 800 mg/day also shows no accululation, with Css of 3.5 and 6.0 mg/L, respectively. Multiple-dose studies in cancer patients show pharmacokinetics comparable with those in healthy populations at similar dosages. Thalidomide exhibits a dose-proportional increase in AUC at doses from 50 to 400mg. Because of the low solubility of thalidomide Cmax is less than proportional to dose, and tmax is prolonged with increasing dose. Age, sex and smoking have no effect on the pharmacokinetics of thalidomide, and the effect of food is minimal. Thalidomide does not alter the pharmacokinetics of oral contraceptives, and is also unlikely to interact with warfarin and grapefruit juice. Since thalidomide is mainly hydrolysed and passively excreted, its pharmacokonetics are not expected to change in patients with impaired liver...(AU). Descriptors: TALIDOMIDA/admin TALIDOMIDA/sint quim TALIDOMIDA/contra TALIDOMIDA/hist TALIDOMIDA/isol TALIDOMIDA/farmacocin TALIDOMIDA/normas TALIDOMIDA/tox TALIDOMIDA/uso terap TALIDOMIDA/metab - ERITEMA NODOSO HANSENICO/quimioter  ERITEMA NODOSO/etiol  SINDROME DE IMUNODEFICIÊNCIA ADQUIRIDA FELINA/terap  ADMINISTRACAO ORAL  INTERACOES DE MEDICAMENTOS/fisiol  RIFAMPINA/antag  FENOBARBITAL/antag  CIMETIDINA/antag  DILTIAZEM/antag  WARFARIN/antag Limits: HUMANO Location: BR191.1; 00948/s

12 / 182

HANSEN

select to print

Id: 18410 Author: Cottini, G. B Title: Contributo allo studio di tre casi di lepra con particolare ricuardo alla bacillemia ?- Source: s.l; s.n; 1933. 29p p. . Descriptors: HANSENIASE/compl HANSENIASE/quimioter HANSENIASE/microbiol HANSENIASE/terap ERITEMA NODOSO/etiol ERITEMA NODOSO/patol ERITEMA MULTIFORME/etiol ERITEMA MULTIFORME/patol SISTEMA NERVOSO PERIFERICO/les SISTEMA NERVOSO PERIFERICO/microbiol SISTEMA NERVOSO PERIFERICO/fisiopatol - HANSENOSTATICOS/uso terap  IODO/uso terap  OURO/uso terap  HELIOTERAPIA  MYCOBACTERIUM LEPRAE/isol  CELULAS SANGUINEAS/citol Limits: HUMANO Location: BR191.1; 01780/s

13 / 182

HANSEN

select to print

Id: 18307 Author: Mansfield, R. E Title: Histology of reactions in leprosy ..- Source: s.l; s.n; 1966. 5 p. . Descriptors: ERITEMA NODOSO/fisiopatol HANSENIASE/compl HANSENIASE/fisiopatol Limits: ESTUDO COMPARATIVO Location: BR191.1; 01183/d.a

14 / 182

HANSEN

select to print

Id: 18246 Author: Romero L., Arturo. Title: Tratamiento de la iridociclitis en enfermos de lepra / Treatment of the iridociclitis in leprosy patients Source: In: Anon.Revista médica de Costa Rica. San Jose, s.n, 1950. p.264-264tab. Abstract: Las iridociclitis que aparece con frecuencia durante la reaccion leprosa, mejora rapidamente, en 3 dias, con un gramo diario de Estreptomicina en un litro de suero glucosado. La Estreptomicina sola o el suero glucosado no dan ningun resultado satisfactorio. (AU). Descriptors: HANSENIASE DIMORFA/compl HANSENIASE DIMORFA/fisiopatol HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/fisiopatol HANSENIASE/compl HANSENIASE/fisiopatol ERITEMA NODOSO/compl ERITEMA NODOSO/fisiopatol Limits: RELATO DE CASO HUMANO CRIANÇA Location: BR191.1; 08950/S

15 / 182

HANSEN

select to print

Id: 18112 Author: Pinto, Juliao Owen Title: Reaccao leprotica ocorrida no puerperio Leprosy reaction in puerperium- Source: s.l; s.n; 1967. 4 p. ilus. Abstract: O A. relata um caso de reaccao leprotica de intensidade invulgar ocorrido imediatamente apos o parto, numa doente sofrendo recidiva de lepra lepromatosa. O aparecimento de recidiva deu-se seis anos apos ser considerada branqueada, tempo durante o qual permaneceu sem sintomatologia clinica ou laboratorial tradutora de actividade. durante a recidiva que durava desde ha quatro anos, sofreu varios susrtos de E.N., bem tolerados. Os dois periodos de gravidez sofridos consideram-se como factores importantes no agravamento da infeccao, e o ultimo parto actuado como "stress", desencadeante do surto intenso de lepro-reaccao. (AU). Descriptors: HANSENIASE/compl HANSENIASE/epidemiol HANSENIASE/prev HANSENIASE/fisiopatol ERITEMA NODOSO/compl ERITEMA NODOSO/fisiopatol Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 00821/s

16 / 182

HANSEN

select to print

Id: 18096 Author: Hamerlinck, F. F; Faber, W. R; Klatser, P. R; Bos, J. D Title: Neopterin as a marker for reactional leprosy ..- Source: s.l; s.n; 1992. 1 p. . Descriptors: HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag NEOPTERINA/imunol NEOPTERINA/farmacocin - ERITEMA NODOSO/fisiopatol Location: BR191.1; 00249

17 / 182

HANSEN

select to print

Id: 18095 Author: Hamerlinck, F. F; Faber, W. R; Klatser, P. R; Bos, J. D Title: Neopterin as a marker for reactional leprosy ..- Source: s.l; s.n; 1992. 1 p. . Descriptors: HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag NEOPTERINA/imunol NEOPTERINA/farmacocin - ERITEMA NODOSO/fisiopatol Location: BR191.1; 00249

18 / 182

HANSEN

select to print

Id: 18018 Author: Kaplan, Gilla. Title: Lepra / Leprosy Source: In: Goldman, Lee; Bennet, J Claude.Cecil: tratado de medicina interna. Rio de Janeiro, Guanabara koogan, 2001. p.1933-1939ilus, tab. Descriptors: HANSENIASE/compl HANSENIASE/diag HANSENIASE/genet HANSENIASE/imunol HANSENIASE/prev HANSENIASE/fisiopatol HANSENIASE/reabil HANSENIASE/terap - ERITEMA NODOSO/compl  ERITEMA NODOSO/diag  ERITEMA NODOSO/fisiopatol Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; WB100, G569C, v.2

19 / 182

HANSEN

select to print

Id: 17982 Author: Naafs, Bernard. Title: Clinical aspects of the reversal reaction. Source: Hansen. int;(n.esp):72-77, Jun. 1998. ilus, tab. Conference: Present in: Congresso da Associação Brasileira de Hansenologia, IX, Foz do Iguaçu, 04-08 junho 1997. Descriptors: HANSENIASE/compl HANSENIASE/imunol ERITEMA NODOSO/compl ERITEMA NODOSO/imunol Limits: RELATO DE CASO ESTUDO COMPARATIVO HUMANO Location: BR191.1

20 / 182

HANSEN

select to print

Id: 17965 Author: DiCaudo DJ Title: Coccidioidomycosis: a review and update Coccidioidomycosis: a review and update-v.55 Source: s.l; s.n; 2006. 13 p. ilus, mapas. Abstract: Coccidioidomycosis occurs in arid and semi-arid regions of the New World from the western United States to Argentina. Highly endemic areas are present in the southwest United States. Coccidioides species live in the soil and produce pulmonary infection via airborne arthroconidia. The skin may be involved by dissemination of the infection, or by reactive eruptions, such as a generalized exanthem or erythema nodosum. Interstitial granulomatous dermatitis and Sweet's syndrome have recently been recognized as additional reactive signs of the infection. Coccidioidomycosis is a [quot ]great imitator[quot ] with protean manifestations. Cutaneous findings may be helpful clues in the diagnosis of this increasingly important disease.(AU). Descriptors: COCCIDIOIDOMICOSE/compl COCCIDIOIDOMICOSE/diag COCCIDIOIDOMICOSE/microbiol COCCIDIOIDOMICOSE/parasitol ERITEMA NODOSO/compl ERITEMA NODOSO/diag ERITEMA NODOSO/epidemiol ERITEMA NODOSO/fisiopatol ERITEMA MULTIFORME/compl ERITEMA MULTIFORME/diag ERITEMA MULTIFORME/epidemiol ERITEMA MULTIFORME/fisiopatol - GRANULOMA/compl  GRANULOMA/diag  GRANULOMA/fisiopatol Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 00327/cme

---

page 1 de 10

go to page

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information